Kathmere Capital Management LLC Acquires New Position in Becton, Dickinson and Company $BDX

Kathmere Capital Management LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the first quarter, according to its most recent filing with the SEC. The firm bought 3,411 shares of the medical instruments supplier’s stock, valued at approximately $536,000.

A number of other hedge funds have also bought and sold shares of BDX. Stephens Inc. AR lifted its stake in shares of Becton, Dickinson and Company by 5.6% during the first quarter. Stephens Inc. AR now owns 16,196 shares of the medical instruments supplier’s stock worth $2,546,000 after buying an additional 866 shares during the period. K.J. Harrison & Partners Inc increased its position in shares of Becton, Dickinson and Company by 28.6% in the 1st quarter. K.J. Harrison & Partners Inc now owns 4,500 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 1,000 shares during the period. Howe & Rusling Inc. raised its stake in Becton, Dickinson and Company by 32.8% in the 1st quarter. Howe & Rusling Inc. now owns 32,547 shares of the medical instruments supplier’s stock worth $5,117,000 after acquiring an additional 8,036 shares during the last quarter. Revisor Wealth Management LLC lifted its position in Becton, Dickinson and Company by 1.1% during the 1st quarter. Revisor Wealth Management LLC now owns 11,285 shares of the medical instruments supplier’s stock worth $1,777,000 after acquiring an additional 118 shares during the period. Finally, Hudson Edge Investment Partners Inc. lifted its position in Becton, Dickinson and Company by 4.6% during the 1st quarter. Hudson Edge Investment Partners Inc. now owns 44,745 shares of the medical instruments supplier’s stock worth $7,035,000 after acquiring an additional 1,953 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BDX. Piper Sandler reduced their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Barclays raised their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a report on Monday. Finally, Argus reduced their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $180.29.

Becton, Dickinson and Company Stock Up 0.5%

Shares of BDX stock opened at $156.36 on Wednesday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock has a market cap of $43.08 billion, a P/E ratio of 39.58, a P/E/G ratio of 11.01 and a beta of 0.21. The stock has a 50 day moving average of $148.08 and a 200 day moving average of $168.55. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter last year, the company earned $3.35 EPS. The business’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Insider Transactions at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 5,188 shares of company stock valued at $765,120. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.